上海市锦天城律师事务所 关于天域生物科技股份有限公司 2026 年第一次临时股东会的 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址：上海市浦东新区银城中路 501 号上海中心 11、12 层 电话: 021-20511000 传真: 021-20511999 邮编: 200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于天域牛物科技股份有限公司 2026年第一次临时股东会的法律意见书 致:天域生物科技股份有限公司 上海市锦天城律师事务所(以下简称"本所")接受天域生物科技股份有限 公司(以下简称"公司") 委托. 就公司召开 2026年第一次临时股东会(以下 简称"本次股东会")的有关事宜,根据《中华人民共和国公司法》(以下简称 "《公司法》")《上市公司股东会规则》等法律、法规和其他规范性文件以及 《天域生物科技股份有限公司章程》(以下简称"《公司章程》")的有关规定, 出具本法律意见书。 为出具本法律意见书. 本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定,严格履行 了法定职责, ...

Core Viewpoint - Tianyu Biological (603717.SH) is currently trading at 7.68 yuan, reflecting a decline of 2.04% and is in a state of breaking its initial public offering price [1] Group 1: Company Overview - Tianyu Biological was previously known as Tianyu Ecology and will officially change its name on August 21, 2024, while retaining its stock code 603717 [1] - The company was listed on the Shanghai Stock Exchange on March 27, 2017, with an issuance of 43.1779 million shares at a price of 14.63 yuan per share [1] Group 2: Fundraising and Financials - The total amount raised from the initial public offering was 631.6927 million yuan, with a net amount of 570.1861 million yuan after expenses [2] - The total issuance costs for the IPO were 61.5066 million yuan, including an underwriting fee of 52.7196 million yuan [3] - Tianyu Biological's previous fundraising totaled 1.034 billion yuan, with a non-public offering of 48.35 million shares at a price of 8.32 yuan per share, raising 402.272 million yuan [4][5]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

Group 1 - The core point of the article is that Tianyu Biological (603717.SH) announced that its actual controller, Luo Weiguo, has received a notice of investigation from the China Securities Regulatory Commission (CSRC) for suspected illegal reduction of shares [1] - The company stated that this investigation is related to the personal conduct of its actual controller and is not connected to the company's operations, indicating that there will be no impact on the company's production and business activities [1][1] - In March 2022, the Shanghai Stock Exchange issued a decision to criticize Luo Weiguo for failing to timely disclose changes in shareholding after a private placement diluted his holdings, which violated the stock exchange's listing rules [1][1]

Group 1 - The chairman and actual controller of Tianyu Biological, Luo Weiguo, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected illegal stock reduction [1][3] - Tianyu Biological announced that the investigation is related to Luo Weiguo's personal actions and will not affect the company's operations or subsidiaries [3] - As of the end of Q3 2025, Luo Weiguo holds 37.25 million shares, accounting for 12.84% of Tianyu Biological, making him the largest shareholder [3] Group 2 - Tianyu Biological has provided guarantees totaling 1.039 billion yuan, which is 200.22% of the company's most recent audited net assets [5] - The company signed a guarantee contract with Hubei Zhijiang Rural Commercial Bank to support cooperative breeding operations, with a maximum guarantee amount of 4.9 million yuan [5] - For the year 2026, Tianyu Biological plans to provide guarantees not exceeding 50 million yuan to breeding farmers, aligning with industry practices and supporting the company's strategic development [5] Group 3 - Tianyu Biological's main business focuses on three core sectors: ecological agriculture and animal husbandry, ecological energy, and ecological environment [6] - As of December 31, the stock price of Tianyu Biological was 7.84 yuan per share, with a total market capitalization of 2.3 billion yuan [7]

Core Viewpoint - Tianyu Biological's chairman, Luo Weiguo, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected illegal stock reduction, which is a personal investigation and does not affect the company's operations [2][4][6][7]. Group 1: Investigation Details - The CSRC issued a notice of investigation (No. 0152025014) to Luo Weiguo regarding his alleged illegal reduction of Tianyu Biological's shares [4][6]. - Luo Weiguo holds 37,251,829 shares, accounting for 12.84% of the total shares, making him the largest shareholder of Tianyu Biological [7][8]. Group 2: Company Operations and Financials - As of December 31, 2025, Tianyu Biological's stock price was 7.84 yuan per share, with a total market capitalization of 2.3 billion yuan [12]. - The company has provided guarantees totaling 1.039 billion yuan, which is 200.22% of its most recent audited net assets, to support cooperative breeding operations [10]. - Tianyu Biological plans to provide up to 50 million yuan in guarantees for breeding farmers in 2026, aligning with industry practices and supporting its pig breeding business [10][11].

天域生物（603717）(603717.SH)发布公告，公司收到公司实际控制人罗卫国先生的通知，其于近日收 到中国证券监督管理委员会(以下简称"中国证监会")下发的《立案告知书》(编号：证监立案字 0152025014号)。因罗卫国先生涉嫌违规减持天域生物股票，根据《中华人民共和国证券法》《中华人 民共和国行政处罚法》等法律法规，中国证监会决定对其立案。 ...

| | | 1月5日A股投资避雷针 | | --- | --- | --- | | 类别 | 公司 | 主要内容 | | 股东减持 | ST路通 | 吴爱军拟减持不超过3%股份 | | | 绿岛风 | 实际控制人的一致行动人拟减持不超过1%股份 | | | 凌志软件 | 股东周颖拟减持合计不超过328.1万股的公司股份 | | | 甲魂网络 | 股东余晓亮合计减持179.7万股公司股份 | | | 科博达 | 范建华已减持1.12万股公司股份 | | | 维科技术 | 工业投资已减持87.79万股公司股份 | | | 奥康国际 | 股东项今羽累计减持178.49万股公司股份 | | | 江龙脂艇 | 晏志清累计减持2%股份 | | | 海能实业 | 周洪军累计减持1.2%股份 | | | 北方股份 | 特沃上海合计减持0.87%公司股份 | | | 雷迪克 | 添益1号减持合计201万股公司股份 | | | 双林股份 | 副总经理陈有甫拟减持不超过12万股 | | | 联动科技 | 实际控制人累计减持2.98%股份 | | 其他 | 大域生物 | 实控人罗卫国涉嫌违规减持股份被证监会立案 | | | 中恒电气 ...

智通财经APP讯，天域生物(603717.SH)发布公告，公司收到公司实际控制人罗卫国先生的通知，其于 近日收到中国证券监督管理委员会(以下简称"中国证监会")下发的《立案告知书》(编号：证监立案字 0152025014号)。因罗卫国先生涉嫌违规减持天域生物股票，根据《中华人民共和国证券法》《中华人 民共和国行政处罚法》等法律法规，中国证监会决定对其立案。 ...

天域生物表示，本次立案系对公司实际控制人的个人调查，与上市公司无关，不会对上市公司及子公司 生产经营活动产生影响。立案调查期间，罗卫国将积极配合证监会的立案调查工作。公司将持续关注上 述事项的进展情况，并严格按照有关规定履行信息披露义务。 北京商报讯（记者 马换换 王蔓蕾）12月31日晚间，天域生物（603717）披露公告称，公司收到公司实 际控制人罗卫国的通知，其于近日收到证监会下发的《立案告知书》。因罗卫国涉嫌违规减持天域生物 股票，证监会决定对其立案。 ...